{
    "1": {
        "workup": {
            "history and physical": [],
            "imaging": ["Chest/abdominal/pelvic CT with contrast and/or PET-CT"],
            "blood chemistry": [
                "Complete blood count, differential, platelet count",
                "Peripheral blood smear",
                "Serum uric acid, serum LDH, beta-2 microglobulin", 
                "Serum quantitative immunoglobulins, serum protein electrophoresis, serum immunofixation electrophoresis",
                {
                    "Comprehensive Metabolic Panel": {
                        "Including BUN, creatinine, electrolytes, albumin, calcium, and liver function tests": "Creatinine clearance"
                    }
                }
            ], 
            "pathology": [
                {
                    "Hematopathology review of all slides with at least one paraffin block representative of the tumor": "Rebiopsy if consult material is nondiagnostic"
                }, 
                "Adequate tissue biopsy for immunophenotyping to establish diagnosis",
                {
                    "Unilateral bone marrow aspirate and biopsy, including immunohistochemistry and/or multi-parameter flow cytometry": [
                        "Bone marrow infiltration by small lymphocytes, plasmacytoid cells, and plasma cells",
                        "Diffuse, interstitial, or nodular pattern of bone marrow infiltration",
                        {
                            "sIgM+, CD19+, CD20+, CD22+": "IgM monoclonal gammopathy of any concentration"
                        }, 
                        "Lymphoplasmacytic cells in  the bone marrow",
                        {
                            "Bone marrow aspirate tested for MYD88 (L265P)": "Allele-specific polymerase chain reaction"
                        }

                    ]
                }
            ], 
            "Other: useful in certain circunstances": [
                "Serum viscosity", 
                "CXCR4 gene mutation testing for patients being considered for Bruton’s tyrosine kinase (BTK) inhibitors",
                "Testing for hepatitis B (if rituximab planned), hepatitis C,f and HIV",
                {
                    "Cryocrit": "If positive = repeat testing of initial serum IgM, and obtain all subsequent serum IgM levels under warm conditions"
                },
                "Consider coagulation and/or von Willebrand disease testing if symptoms present (excess bruising or bleeding) or if clinically indicated", 
                "Cold agglutinins", 
                "Neurology consult", 
                "Anti-myelin-associated glycoprotein (MAG) antibodies/anti-GM1",
                "Nerve conduction study (NCS)/electromyogram (EMG)",
                "Fat pad sampling and/or congo red staining of bone marrow for amyloid",
                "Retinal examination (if IgM ≥3.0 g/dL or if hyperviscosity is suspected)", 
                "24-h urine for total protein, urine protein electrophoresis (UPEP), and urine immunofixation electrophoresis (UIFE)", 
                "Amyloid tissue subtyping with mass spectrometry, if indicated"
            ], 
            "Other Consider when": [
                "Hyperviscosity", 
                "Neuropathy", 
                "Organomegaly", 
                "Amyloidosis", 
                "Cold agglutin disease", 
                "Cryoglubulinemia", 
                "Anemia and other cytopenias associated with disease", 
                "Bulky adenopathy", 
                "B symptoms"
            ]
        }, 
        "treatment": {
            "If hyperviscosity, neuropathy, symptomatic adenopathy or organomegaly, amyloidosis, cryoglobulinemia cold agglutinin disease, anemia, and presence of cytopenia": {
                "If candidates for hematopoietic cell transplantation (HCT)": [
                    "Exposure to nucleoside analogs (fludarabine and cladribine) should be avoided in patients who may be potential autologous HCT candidates"
                ], 
                "Initial plasmapheresis": [
                    "In patients with symptomatic hyperviscosity, plasmapheresis should first be performed",
                    {
                        "Plasmapheresis should also be considered before treatment with rituximab or ofatumumab for asymptomatic Waldenström macroglobulinemia patients with an IgM ≥4000 mg/ dL or who are symptomatic to avoid aggravation of serum viscosity based on rituximab-related IgM flare": ["Rituximab or ofatumumab may also be held in patients with elevated serum IgM levels for initial treatment cycles"]
                    }, 
                    "Blood warmers should be used for apheresis if cryoprecipitate or cryoglobulin are present."
                ], 
                "Systemic treatment": [
                    {
                        "Subcutaneous bortezomib is the preferred method of administration": ["Both weekly and twice-weekly dosing schemas of bortezomib may be appropriate"]
                    },
                    "Carfilzomib may be used once or twice weekly and at different doses",
                    "Rituximab and hyaluronidase human injection for subcutaneous administration may be substituted for rituximab after patients have received the first full dose of rituximab by intravenous infusion.",
                    {
                        "Preferred regimens": [
                            "Bendamustine/rituximab", 
                            "Bortezomib/dexamethasone/rituximab",
                            "Ibrutinib ± rituximab",
                            "Zanubrutinib"
                        ], 
                        "Other recommended regimens": [
                            "Bendamustine", 
                            "Carfilzomib/rituximab/dexamethasone", 
                            "Ixazomib/rituximab/dexamethasone",
                            "Rituximab", 
                            "Rituximab/cyclophosphamide/dexamethasone", 
                            "Rituximab/cyclophosphamide/prednisone"
                        ]
                    }
                ]
            },
            "Prophylaxis": [
                "Pneumocystis jiroveci pneumonia (PJP) prophylaxis should be considered for patients receiving bendamustine/rituximab or fludarabine/ cyclophosphamide/rituximab.", 
                "Administer herpes zoster prophylaxis for all patients treated with proteasome inhibitors and nucleoside analogs.",
                {
                    "Prophylactic antiviral therapy with entecavir is recommended for any patient who is hepatitis B surface antigen-positive and receiving antiCD20 therapy": [
                        "If there is active disease (PCR+), it is considered treatment/management and not prophylactic therapy.",
                        "In cases of hepatitis B core antibody positivity, prophylactic antiviral therapy is preferred"
                    ]
                }
            ]

        }, 
        "followup": {
            "if low risk": ["Monitor every 12 months with complete blood count, Comprehensive Metabolic Panel, serum protein electrophoresis, serum immunoglobulins"],
            "if intermediate risk": ["Monitor every 6 months with complete blood count, Comprehensive Metabolic Panel, serum protein electrophoresis, serum immunoglobulins"],
            "If high risk": ["Monitor every 3 months with complete blood count, Comprehensive Metabolic Panel, serum protein electrophoresis, serum immunoglobulins"]
        }, 
        "response criteria": {
            "Complete response": [
                "IgM in normal range, and disappearance of monoclonal protein by immunofixation",
                "No histologic evidence of bone marrow involvement, and resolution of any adenopathy/organomegaly (if present at baseline), along with no signs or symptoms attributable to WM.", 
                "Reconfirmation of the CR status is required by repeat immunofixation studies."
            ],
            "Very good partial response": [
                "A ≥90% reduction of serum IgM and decrease in adenopathy/organomegaly (if present at baseline) on physical examination or on CT scan"
            ],
            "Partial response": [
                "A ≥50% reduction of serum IgM and decrease in adenopathy/organomegaly (if present at baseline) on physical examination or on CT scan"
            ],
            "Minor response": [
                "A ≥25% but <50% reduction of serum IgM",
                "No new symptoms or signs of active disease"
            ],
            "Stable disease": [
                "A <25% reduction and <25% increase of serum IgM without progression of adenopathy/organomegaly, cytopenias, or clinically significant symptoms due to disease and/or signs of WM"
            ],
            "Progressive disease": [
                "A ≥25% increase in serum IgM by protein confirmed by a second measurement or progression of clinically significant findings due to disease (anemia, thrombocytopenia, leukopenia, bulky adenopathy/ organomegaly) or symptoms (unexplained recurrent fever ≥38.4°C, drenching night sweats, ≥10% body weight loss, or hyperviscosity, neuropathy, symptomatic cryoglobulinemia, or amyloidosis) attributable to WM."
            ]
        }
    }, 
    "2": {
        "workup": {
            "history and physical": [],
            "imaging": ["Brain and entire spine MRI with gadolinium enhancement"],
            "Pathology: in certain circumstances": [
                "Biopsy of affected tissue", 
                "Concurrent bone marrow aspiration and biopsy for IgH gene rearrangement and MYD88 L265P testing"
            ],
            "other": ["Lumbar puncture for cerebrospinal fluid analysis (cytology, multiparameter flow cytometry, PCR for IgH gene rearrangement, PCR for MYD88 L265P)"]
        }, 
        "treatment": {
            "Asymptomatic": ["Observation"],
            "Symptomatic": {
                "Preferred Regimens": [
                    "Ibrutinib", 
                    "Zanubrutinib" 
                ],
                "Other Recommended Regimens": [
                    "Bendamustine", 
                    "Cytarabine", 
                    "Fludarabine", 
                    "Methotrexate", 
                    "Intrathecal methotrexate", 
                    "Radiotherapy"
                ]
            }
        }, 
        "followup": {} 
    }
}